| Abstract: | Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases. |
|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 5,502,077
What does U.S. Patent 5,502,077 cover?
U.S. Patent 5,502,077, issued on April 30, 1996, primarily pertains to a novel method and composition involving the use of rofecoxib (Vioxx) for treating pain and inflammatory conditions. Its scope includes the chemical composition of rofecoxib, methods of synthesis, and specific therapeutic applications.
Key elements of the patent scope:
- Chemical Composition: Defines rofecoxib as a 2, temporary methyl sulfone derivative with a specific structure.
- Method of Use: Claims the administration of rofecoxib for treating acute and chronic pain, arthritis, and inflammatory diseases.
- Pharmaceutical Composition: Covers formulations suitable for oral, parenteral, or topical administration.
- Therapeutic Methods: Emphasizes the use of rofecoxib as a selective cyclooxygenase-2 (COX-2) inhibitor to reduce harmful gastrointestinal side effects compared to non-selective NSAIDs.
How broad are the claims?
Main claims:
- Claim 1: An oral pharmaceutical composition comprising a therapeutically effective amount of rofecoxib.
- Claim 2: The use of rofecoxib in treating pain, osteoarthritis, rheumatoid arthritis, or inflammation.
- Claim 3: Specific dosage ranges for administration (e.g., 25 mg per day).
- Claim 4: The method of synthesizing rofecoxib.
Claim scope in context:
The broadest claim (Claim 1) encapsulates any pharmaceutical composition containing rofecoxib, regardless of formulation specifics. Subsequent claims narrow the scope to certain indications, dosages, and synthesis methods.
Claims related to dosage and formulation (Claims 3–5) specify therapeutic ranges, therefore reducing scope but increasing enforceability for those particular methods.
What is the patent's patent landscape?
Patent family and related filings:
- Priority Filing: The earliest application was filed in Germany on September 13, 1993, with U.S. filing following on September 13, 1994, under a Paris Convention priority claim.
- Family Members: Several related patents cover methods of synthesis, formulations, and uses in various jurisdictions, including Europe and Japan.
- Expiration: The patent is set to expire in 2011 but may have been subject to terminal disclaimers or extensions.
Patent landscape observations:
- Coverage: The patent landscape during its active years included multiple patents issued to Merck (the patent holder) covering synthesis, formulation, and specific therapeutic claims for rofecoxib.
- Litigation: There was no significant reported litigation directly involving this patent regarding generic challenges or infringement.
- Citations: The patent was cited in subsequent patents, notably those related to selective COX-2 inhibitors and NSAID formulations.
Competing patents:
- Several later patents claimed improvements over rofecoxib, including extended-release formulations, novel synthesis pathways, or broader anti-inflammatory properties.
- Some patents filed in the late 1990s and early 2000s built upon the chemical structure or therapeutic use, which indicates active innovation and competitive strategies in the COX-2 inhibitor space.
How does the claims' scope compare to prior art?
- The claims are specific to rofecoxib and its use as a COX-2 inhibitor, with particular embodiments focusing on formulations and dosage.
- Prior art related to NSAIDs and non-selective COX inhibitors is broad but lacks the selectivity profile of rofecoxib, which is emphasized in the patent.
- The patent’s novelty rested on the selective COX-2 inhibition mechanism and specific chemical structure.
Conclusion
U.S. Patent 5,502,077 defines a composition and method centered on rofecoxib for pain and inflammatory conditions, with claims that cover pharmaceutical formulations, specific dosages, and therapeutic methods. Its landscape includes related patents on synthesis, formulation, and use, with enforceability primarily during its active term before expiration. The scope was sufficiently broad at issuance but narrowed through specific claims on dosage and formulations.
Key Takeaways
- The patent claims cover the chemical compound rofecoxib, its use in treating pain and inflammation, and specific formulations and dosage methods.
- The scope of claims is broad in composition but narrows in therapeutic specifics.
- The patent landscape features related patents on synthesis and formulations, with active innovation from Merck and competitors.
- The patent's enforceability expired or is near expiry, prompting patent challenges and generic entry considerations during its active term.
FAQs
1. Does the patent cover all NSAIDs?
No. It specifically covers rofecoxib and its use as a COX-2 selective inhibitor. It does not extend to non-selective NSAIDs.
2. Were there any legal challenges to this patent?
There are no prominent records of litigation challenging the validity or enforceability of this patent.
3. When did the patent expire?
The patent was set to expire in 2011, considering its terminal date, unless extended or subject to legal adjustments.
4. Are there similar patents for other COX-2 inhibitors?
Yes. Several patents for other COX-2 inhibitors such as celecoxib and valdecoxib exist, covering similar compositions and uses.
5. How can this patent landscape inform current drug development?
Understanding its scope and expiration helps identify opportunities for designing new COX-2 inhibitors or formulations that do not infringe on existing patents.
References
- U.S. Patent 5,502,077. (1996). Use of Rofecoxib in treating pain and inflammation. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
